Logo Image
News|Articles|October 1, 2026

Nail Detachment 4 Times More Common With GLP-1 Use

Fact checked by: Tim Smith
Listen
0:00 / 0:00

Key Takeaways

  • Onycholysis prevalence was 39% in GLP-1 users versus 9% in controls, with at least one nail disorder (66% vs 53%) and discoloration (46% vs 17%).
  • Persistence of differences after stratifying for weight loss and adjusting for dermatologic conditions/nutritional deficiencies suggests effects not solely attributable to rapid weight reduction.
SHOW MORE

The first controlled study of GLP-1 receptor agonists and nail health found nail detachment in 39% of users versus 9% of controls at EADV 2026.

Nail detachment was more than 4 times as common among people taking GLP-1 receptor agonists compared with metabolically similar controls, according to the first controlled study examining GLP-1 receptor agonists' effects on nail health, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, held September 30-October 3 in Vienna, Austria.¹

GLP-1 receptor agonists are increasingly prescribed for type 2 diabetes and obesity, but data on their dermatologic effects on nails, hair, and scalp have been limited largely to isolated case reports and pharmacovigilance signals.¹ Researchers compared 575 GLP-1 receptor agonist users with 1329 people with type 2 diabetes or obesity who had never taken the drugs, recruited across France, the United States, Brazil, and Mexico.¹ A companion cross-sectional study using the same cohort examined hair and scalp changes among GLP-1 users.2

"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," said investigator Charles Taïeb, MD, PhD, Managing Director at European Market Maintenance Assessment, in EADV Q&A. "Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself."¹

GLP-1 Receptor Agonist Nail Study Design and Detachment Findings

The multinational, cross-sectional, case-control study compared nail outcomes between 575 GLP-1 receptor agonist users and 1329 controls with type 2 diabetes and/or obesity who had never used the drug class.¹ Nail detachment, or onycholysis, was reported by 39% of GLP-1 users compared with 9% of controls.¹ At least 1 nail disorder was reported by 66% of GLP-1 users versus 53% of controls, and nail discoloration affected 46% of users compared with 17% of controls.¹

The elevated prevalence of nail changes did not appear to be explained by weight loss alone, as differences between GLP-1 users and controls remained significant when researchers isolated participants who had lost weight.¹ After adjusting for dermatological conditions and nutritional deficiencies, nail detachment and discoloration remained roughly 2 to 3 times more frequent among GLP-1 users.¹ Around half of users reported nail problems before starting GLP-1 therapy, a confounding factor the researchers say tempers causal interpretation of the findings.¹

GLP-1 Hair and Scalp Findings and Study Limitations

Key Facts

  • Nail detachment was reported by 39% of GLP-1 receptor agonist users compared with 9% of controls, more than 4 times the rate in a multinational controlled study of 575 users and 1329 controls
  • At least 1 nail disorder was reported by 66% of users versus 53% of controls, and nail discoloration affected 46% versus 17%
  • A companion study found unusual hair loss in 50% of users versus 34% of controls, with scalp inflammation accompanying most cases
  • Differences persisted after adjusting for weight loss, dermatological conditions, and nutritional deficiencies, though about half of users reported nail problems before starting treatment
  • Researchers are planning prospective studies with standardized dermatologic exams and biological monitoring to clarify causation and reversibility

In the companion hair and scalp study, unusual hair loss was reported by 50% of GLP-1 users compared with 34% of controls, and loss of hair volume or density affected 42% of users versus 19% of controls.2 Hair loss beginning after treatment initiation was more than twice as common among users (26% vs 12%), and scalp redness was roughly 3 times more frequent among users than controls.2 Hair loss rarely occurred in isolation among GLP-1 users, with most cases accompanied by scalp symptoms including itching, redness, or scaling.

"This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component," explained Bruno Halioua, dermatologist, Institut Alfred Fournier, Paris. "Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable."³

Both studies were cross-sectional and relied on patient-reported symptoms, meaning they can identify associations but cannot establish causation between GLP-1 therapy and the observed changes.¹ Halioua said the findings should prompt awareness rather than alarm, noting the changes are frequent and usually benign.2 The researchers plan prospective studies following patients from treatment initiation using standardized dermatologic exams, including trichoscopy and onychoscopy, alongside biological monitoring of iron, zinc, vitamin B12, vitamin D, and protein status.

References
  1. Khalfalla T, Taïeb C, et al. Nail detachment over 4 times more common among GLP-1 users, first controlled study finds. Presented at: European Academy of Dermatology and Venereology (EADV) Congress 2026; September 30-October 3, 2026; Vienna, Austria.
  2. Halioua B, et al. Hair and scalp changes among GLP-1 receptor agonist users: a companion cross-sectional study. Presented at: European Academy of Dermatology and Venereology (EADV) Congress 2026; September 30-October 3, 2026; Vienna, Austria.

Related to this article

View more